Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma

Aydin D., Sendur M. A. , KEFELİ U., Ustaalioglu B. B. , Aydin O., Yildirim E., ...Daha Fazla

CLINICAL COLORECTAL CANCER, cilt.16, sa.1, ss.78-83, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 16 Konu: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.clcc.2016.04.013
  • Sayfa Sayıları: ss.78-83


Small bowel adenocarcinomas (SBAs) are rarely seen tumors of the gastrointestinal system. Data on the usage of chemotherapy together with bevacizumab in SBAs is limited. We analyzed the results of treatment with bevacizumab with or without chemotherapy in 28 patients with SBAs. Although there was a trend toward a survival benefit, we did not find any statistically significant difference with the addition of bevacizumab to the backbone chemotherapy in SBAs.